Advertisement
Document › Details
Shimadzu Corporation. (7/26/11). "Press Release: National Cancer Center (NCC) and Shimadzu Corporation Reach Comprehensive Collaborative Research Agreement".
![]() |
Region | Japan |
![]() |
Organisation | Shimadzu Corporation |
| Group | Shimadzu (Group) | |
| Organisation 2 | National Cancer Center (NCC) (JP) | |
![]() |
Product | mass spectrometry (MS) |
![]() |
Index term | National Cancer Center (JP)–Shimadzu: mass spectrometry, 201106– collab long-term intergration of MS + chromatography with other cancer research techn |
![]() |
Person | Kayama, Takamasa (National Cancer Center (JP) 201106 Chief Director) |
| Person 2 | Nakamoto, Akira (Shimadzu 201106 President) | |
On June 15th 2011, the National Cancer Center (Chief Director: Takamasa Kayama, M.D., Ph.D.; situated in Chuo-ku, Tokyo; referred to herein as the NCC), an independent administrative institution (IAI), reached a comprehensive collaborative research agreement with Shimadzu Corporation (President: Akira Nakamoto; situated in Nakagyo-ku, Kyoto; referred to herein as Shimadzu).
The purpose of this agreement is to develop internationally leading, high-level, cutting-edge medical technologies that contribute to the suppression of cancer and the promotion of human health. These include technological developments related to the realization of ultra-early cancer diagnoses, pharmacokinetic analysis for the achievement of a revolution in the drug discovery process, and medical treatments. These developments will be accomplished through a fusion of the high-level cancer research techniques and clinical experience at the NCC with Shimadzu's cutting-edge technologies in next-generation medical treatment fields.
The primary collaborative and cooperative activities stipulated in this agreement consist of (1) cooperative research and other research collaborations; (2) exchanges of research techniques, research materials, and other research information; (3) exchanges of researchers and technical staff; (4) cultivation of the next generation of researchers and technicians; and (5) promotion of the reciprocal use of the facilities, equipment, and instruments owned by the respective parties.
Established in 1962, the NCC is the leading Japanese medical institution for cancer treatment and research, and has a wealth of experience in terms of clinical studies. In discussing his hopes for collaborative research, Chief Director Kayama of the NCC stated that he would like to see "the union with Shimadzu lead to the development of equipment that can be used throughout the world, so as to effect and advance the change from life science to medical science."
Shimadzu is pursuing research and development in the next-generation medical treatment fields of molecular imaging technology and biomarker searches, based on the fusion and application of its chromatography, mass spectrometry and other core analysis and measuring technology with medical imaging technology. In indicating his ambitions, Shimadzu's President Nakamoto noted that "thus far, the life sciences have been the core enterprise at Shimadzu. In the future, however, I would like to see the biomarker candidates discovered to date applied to ultra-early diagnosis; we believe this can be accomplished through the implementation of clinically useful medical science and a fusion of imaging diagnostics and molecular imaging, in conjunction with the NCC."
To date, the NCC and Shimadzu have pursued collaborative research based on individual themes, including examinations of the clinical applications of the "tomosynthesis" cutting-edge medical imaging technology. By establishing an even closer bond between the parties, leading to the development of revolutionary, next-generation medical treatment systems, this agreement is likely to contribute to reducing the number of people who die from cancer while improving the quality of medical treatment available for cancer patients.
Record changed: 2011-11-25 |
More documents for Shimadzu (Group)
- [1] Shimadzu Corporation. (5/18/12). "Press Release: Shimadzu Corporation Introduces Ultra Fast Triple Quadrupole Gas Chromatograph Mass Spectrometer and Expands LC-MS/MS Portfolio"....
- [2] Shimadzu Corporation. (5/11/12). "Press Release: Presentation – Operating Results and Financial Position Ended March 2012. President & CEO Akira Nakamoto". Kyoto....
- [3] Shimadzu Corporation. (5/11/12). "Press Release: Release of the New EZ Test EZ-X Series. Compact Tabletop Testers Are Ideally Suited for Food Texture Analysis, Pharmaceutical Evaluation, and a Wide Variety of other Testing Applications"....
- [4] Shimadzu Corporation. (5/10/12). "Press Release: Operating Results and Financial Position For the Fiscal Year Ended March 31, 2012". Kyoto....
- [5] [iito] Business Intelligence. (4/20/12). "[MSC] Newsletter March 2012". Bremen....
- [6] Shimadzu Scientific Instruments, Inc.. (4/9/12). "Press Release: Shimadzu Scientific Instruments and the University at Texas at Arlington Form Shimadzu Center for Advanced Analytical Chemistry"....
- [7] University of Texas at Arlington. (4/6/12). "Press Release: Shimadzu Gift Brings Millions in Scientific Equipment to UT Arlington"....
- [8] Shimadzu Corporation. (4/4/12). "Press Release: »Excellence in Science« Established as Brand Statement for Shimadzu Group"....
- [9] Sony DADC. (3/21/12). "Press Release: Shimadzu/Kratos and Sony DADC Sign New Agreement to Extend Collaboration". Manchester....
- [10] Shimadzu Scientific Instruments, Inc.. (3/19/12). "Press Release: New SALD-2300 Achieves Quick, High-resolution Particle Size Distribution Analysis. WingSALD II Software Is World’s First to Provide Automatic Refractive Index Calculation"....
To subscribe to our free, monthly [MSC] Newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
NEW: Visit our brand new forthcoming web portals Life-Sciences-Germany.com and Life-Sciences-Europe.com
» top
![[MSC] Mass-Spec-Capital.com The Mass Spectrometry Web Portal](/images/basics/msc-mass-spectrometry-portal-logo.jpg)










![Banner [iiito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)